Charles Schwab’s PharMerica Corporation PMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
Sell
-269,518
Closed -$7.9M 3077
2017
Q3
$7.9M Buy
269,518
+3,864
+1% +$108K 0.01% 1611
2017
Q2
$6.97M Buy
265,654
+19,780
+8% +$486K 0.01% 1602
2017
Q1
$5.75M Buy
245,874
+23,514
+11% +$580K 0.01% 1679
2016
Q4
$5.59M Buy
222,360
+22,785
+11% +$575K 0.01% 1667
2016
Q3
$5.6M Buy
199,575
+10,095
+5% +$259K 0.01% 1574
2016
Q2
$4.67M Buy
189,480
+8,322
+5% +$206K 0.01% 1601
2016
Q1
$4.01M Buy
181,158
+8,663
+5% +$231K 0.01% 1651
2015
Q4
$6.04M Sell
172,495
-5,045
-3% -$158K 0.01% 1384
2015
Q3
$5.05M Buy
177,540
+2,009
+1% +$67.5K 0.01% 1472
2015
Q2
$5.85M Buy
175,531
+23,939
+16% +$735K 0.01% 1448
2015
Q1
$4.27M Buy
151,592
+18,914
+14% +$470K 0.01% 1613
2014
Q4
$2.75M Sell
132,678
-109,877
-45% -$2.61M ﹤0.01% 1828
2014
Q3
$5.93M Buy
242,555
+3,807
+2% +$101K 0.01% 1221
2014
Q2
$6.83M Buy
238,748
+29,275
+14% +$814K 0.01% 1146
2014
Q1
$5.86M Buy
209,473
+74,585
+55% +$1.83M 0.01% 1207
2013
Q4
$2.9M Sell
134,888
-48,452
-26% -$881K 0.01% 1672
2013
Q3
$2.48M Buy
183,340
+6,334
+4% +$85.3K 0.01% 1717
2013
Q2
$2.44M Buy
+177,006
New +$2.51M 0.01% 1640

Charles Schwab's PMC Position: Q4 2017 in Review

Charles Schwab sold out of PharMerica Corporation (PMC) in Q4 2017, closing a stake of 269,518 shares — an estimated $7.9M sold.

Charles Schwab first reported a position in PMC in Q2 2013 and held it in 18 quarters. The position peaked at $7.9M in Q3 2017. 0 funds tracked by Wall St. Rank hold PMC as of Q4 2017.

  • Charles Schwab reported no remaining PharMerica Corporation position as of Q4 2017 after selling out during the quarter.
  • Charles Schwab sold 269,518 PharMerica Corporation shares in Q4 2017, an estimated $7.9M.
  • Charles Schwab first reported a position in PharMerica Corporation in Q2 2013 and held it in 18 quarters.
  • Charles Schwab's PharMerica Corporation position peaked at $7.9M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held PharMerica Corporation as of Q4 2017.

Based on Charles Schwab's 13F filing for Q4 2017, filed 17 Jan 2018.